: Fractional flow reserve (FFR) assessment represents the most widely used revascularisation strategy of the last two decades. However, many FFR (+) lesions, particularly those in the grey zone, can be safely treated medically, while other lesions carrying vulnerable plaque (VP) features can cause future events despite the absence of ischaemia. Optical coherence tomography (OCT) can identify lesions with VP morphology. The objective of this study is to determine whether a combined revascularisation strategy - targeting only severely ischaemic lesions (FFR ≤0.75) and extending treatment to OCT-assessed VP, even in the absence of ischaemia (FFR>0.80) - could reduce future adverse events compared with the current revascularisation practice based exclusively on the presence of ischaemia (FFR ≤0.80). The COMBINE-INTERVENE Trial is a global, prospective, randomised, single-blinded, sham-controlled, superiority trial. A total of 1,223 all-comer patients with multivessel disease (≥2 lesions with a diameter of stenosis ≥50%) will be randomised 1:1 to revascularisation if the FFR is ≤0.75 or a VP is present (experimental arm) versus FFR ≤0.80 in the comparative arm. The primary endpoint is a composite of cardiac death, any myocardial infarction, or any clinically driven revascularisation within 24 months. The trial has already completed enrolment in 50 centres worldwide. COMBINE-INTERVENE is the first trial evaluating the impact of a revascularisation strategy that targets lesions that are either severely ischaemic or carry an OCT-assessed VP versus revascularisation based on ischaemia alone. The trial is powered for superiority. (ClinicalTrials.gov: NCT05333068).

Kedhi, E., Wojakowski, W., Erlinge, D., Akasaka, T., Roleder, T., Muller, J., Malinowski, K. P., Wlodarczak, A., Wlodarczak, S., Vijayvergiya, R., Patel, T., Spaziano, M., Akl, E., Moreno, R., Brugaletta, S., Nuruddin, A. A., Ping Tsao, T., Bartus, S., Maeng, M., Benedek, T., Postu, M., Van Belle, E., Burzotta, F., Brown, A., Pinilla-Echeverri, N., Prati, F., De Luca, G., Landmesser, U., Oemrawsingh, R. M., Alfonso, F., Combined ischaemia and vulnerable plaque percutaneous coronary intervention to reduce cardiovascular events: design and rationale of the COMBINE-INTERVENE Trial, <<EUROINTERVENTION>>, 2026; (Oct 1): N/A-N/A. [doi:10.4244/EIJ-D-26-00702] [https://hdl.handle.net/10807/350348]

Combined ischaemia and vulnerable plaque percutaneous coronary intervention to reduce cardiovascular events: design and rationale of the COMBINE-INTERVENE Trial

Burzotta, Francesco;Prati, Francesco;
2026

Abstract

: Fractional flow reserve (FFR) assessment represents the most widely used revascularisation strategy of the last two decades. However, many FFR (+) lesions, particularly those in the grey zone, can be safely treated medically, while other lesions carrying vulnerable plaque (VP) features can cause future events despite the absence of ischaemia. Optical coherence tomography (OCT) can identify lesions with VP morphology. The objective of this study is to determine whether a combined revascularisation strategy - targeting only severely ischaemic lesions (FFR ≤0.75) and extending treatment to OCT-assessed VP, even in the absence of ischaemia (FFR>0.80) - could reduce future adverse events compared with the current revascularisation practice based exclusively on the presence of ischaemia (FFR ≤0.80). The COMBINE-INTERVENE Trial is a global, prospective, randomised, single-blinded, sham-controlled, superiority trial. A total of 1,223 all-comer patients with multivessel disease (≥2 lesions with a diameter of stenosis ≥50%) will be randomised 1:1 to revascularisation if the FFR is ≤0.75 or a VP is present (experimental arm) versus FFR ≤0.80 in the comparative arm. The primary endpoint is a composite of cardiac death, any myocardial infarction, or any clinically driven revascularisation within 24 months. The trial has already completed enrolment in 50 centres worldwide. COMBINE-INTERVENE is the first trial evaluating the impact of a revascularisation strategy that targets lesions that are either severely ischaemic or carry an OCT-assessed VP versus revascularisation based on ischaemia alone. The trial is powered for superiority. (ClinicalTrials.gov: NCT05333068).
2026
Inglese
Kedhi, E., Wojakowski, W., Erlinge, D., Akasaka, T., Roleder, T., Muller, J., Malinowski, K. P., Wlodarczak, A., Wlodarczak, S., Vijayvergiya, R., Patel, T., Spaziano, M., Akl, E., Moreno, R., Brugaletta, S., Nuruddin, A. A., Ping Tsao, T., Bartus, S., Maeng, M., Benedek, T., Postu, M., Van Belle, E., Burzotta, F., Brown, A., Pinilla-Echeverri, N., Prati, F., De Luca, G., Landmesser, U., Oemrawsingh, R. M., Alfonso, F., Combined ischaemia and vulnerable plaque percutaneous coronary intervention to reduce cardiovascular events: design and rationale of the COMBINE-INTERVENE Trial, <<EUROINTERVENTION>>, 2026; (Oct 1): N/A-N/A. [doi:10.4244/EIJ-D-26-00702] [https://hdl.handle.net/10807/350348]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/350348
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact